Royalty Pharma plc (RPRX) Earnings History
Annual and quarterly earnings data from 2017 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | 65.6% | 32.4% |
| 2024 | 100.0% | 57.1% | 37.9% |
| 2023 | 100.0% | 63.4% | 48.2% |
| 2022 | 100.0% | 13.7% | 1.9% |
| 2021 | 100.0% | 62.5% | 27.1% |
Download Data
Export RPRX earnings history in CSV or JSON format
Free sign-in required to download data
Royalty Pharma plc (RPRX) Earnings Overview
As of March 5, 2026, Royalty Pharma plc (RPRX) reported trailing twelve-month net income of $765M, reflecting -0.1% year-over-year growth. The company earned $1.37 per diluted share over the past four quarters, with a net profit margin of 0.3%.
Looking at the long-term picture, RPRX's 5-year EPS compound annual growth rate (CAGR) stands at -7.3%, signaling declining earnings. The company achieved its highest annual net income of $2.35B in fiscal 2019.
Royalty Pharma plc maintains positive profitability with, operating margin of 0.7%, and net margin of 0.3%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including LGND ($49M net income, -0.0% margin), INVA ($271M net income, 0.6% margin), BTX (N/A net income, 0.9% margin), RPRX has outperformed on profitability metrics. Compare RPRX vs LGND →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $771M | -10.2% | $1.56B | $1.78 | 32.4% | 65.6% |
| 2024 | $859M | -24.3% | $1.29B | $1.91 | 37.9% | 57.1% |
| 2023 | $1.13B | +2549.5% | $1.49B | $2.53 | 48.2% | 63.4% |
| 2022 | $43M | -93.1% | $307M | $0.10 | 1.9% | 13.7% |
| 2021 | $620M | -36.4% | $1.43B | $1.49 | 27.1% | 62.5% |
| 2020 | $975M | -58.5% | $1.60B | $2.60 | 45.9% | 75.2% |
| 2019 | $2.35B | +70.5% | $2.62B | $6.42 | 129.4% | 144.6% |
| 2018 | $1.38B | +13.9% | $1.36B | $2.27 | 76.8% | 76.0% |
| 2017 | $1.21B | - | $940M | $1.99 | 75.7% | 58.8% |
See RPRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RPRX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare RPRX vs LLY
See how RPRX stacks up against sector leader Eli Lilly and Company.
Start ComparisonFrequently Asked Questions
Is RPRX growing earnings?
RPRX EPS of $1.37 reflects slowing growth at -0.1%, below the 5-year CAGR of -7.3%. TTM net income is $765M. Expansion rate has moderated.
What are RPRX's profit margins?
Royalty Pharma plc net margin is +0.3%, with operating margin at +0.7%. Below-average margins reflect competitive or cost pressures.
How consistent are RPRX's earnings?
RPRX earnings data spans 2017-2025. The current earnings trend is -0.1% YoY. Historical data enables comparison across business cycles.